Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.08.2012 | original article

The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease

verfasst von: Tugrul Purnak, MD, Yavuz Beyazit, MD, Asso. Prof. Ersan Ozaslan, MD, Cumali Efe, MD, Merve Hayretci, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2012

Einloggen, um Zugang zu erhalten

Abstract

Background and aim

Nonalcoholic fatty liver diseases (NAFLD) are a clinical spectrum of disorders, of which nonalcoholic steatohepatitis (NASH) is the most strongly associated with inflammation. Inflammation is a known risk factor for low bone mass in the body. The primary goal of the present study was to evaluate the association between bone mineral density and liver function in patients with NASH.

Materials and methods

Consenting patients with a diagnosis of NAFLD were included in the study. Extent of fatty change was graded based on ultrasonographic appearance (Grade 1, mild; Grade 2, moderate; Grade 3, severe). Bone mineral density was measured using the dual-energy x-ray absorptiometry method. ALT and hs-CRP were considered as noninvasive marker of NASH. According to ALT levels, patients were divided into two subgroups.

Results

A total of 102 patients with NAFLD and 54 healthy controls participated in the study. None of the patients with NAFLD had an abnormal bone mineral density. Furthermore, there was no difference between groups with regard to serum vitamin D levels. A subgroup analysis revealed that female patients with elevated serum ALT level had significantly lower bone mineral densities and higher hsCRP levels than female patients with normal ALT levels. The difference in vitamin D levels and body mass indices between the same subgroups was statistically insignificant.

Conclusions

Simple steatosis of the liver does not affect bone mineral density. However, in a subgroup of patients with NAFLD, the presence of elevated serum ALT and hs-CRP levels, which are suggestive of NASH, was associated with lower bone mineral densities. Better understanding of the biological basis and the complex interactions between NAFLD and bone mass may help guide the clinical management of bone diseases associated with inflammation of the liver.
Vorheriger Artikel Serum lactate level predict mortality in elderly patients with cirrhosis
Nächster Artikel Measuring quality of life with the German Osteoporosis Quality of Life Questionnaire in women with osteoporosis
Literatur
1.
2.
Duvnjak M, Lerotic I, Barsic N,et al. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol. 2007;13:4539–50.PubMed
3.
Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306–17PubMedCrossRef
4.
Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005;42:650–6.PubMedCrossRef
5.
Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the akaike Information criterion scoring system in the general Japanese population. J Gastroenterol. 2009;44:313–21.PubMedCrossRef
6.
Kinjo M, Setoguchi S, Solomon DH. Bone mineral density in adults with the metabolic syndrome: Analysis in a population-based US sample. J Clin Endocrinol Metab. 2007;92:4161–4.PubMedCrossRef
7.
Kelman A, Lane NE. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol. 2005;19:1021–37.PubMedCrossRef
8.
Kotake S, Udagawa N, Hakoda M,et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001;44:1003–12.PubMedCrossRef
9.
Smith BJ, Lerner MR, Bu SY,et al. Systemic bone loss and induction of coronary vessel disease in a rat model of chronic inflammation. Bone 2006;38:378–6.PubMedCrossRef
10.
Caetano-Lopes J, Canhao H, Fonseca JE. Osteoimmunology—the hidden immune regulation of bone. Autoimmun Rev. 2009;8:250–5.
11.
Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut inflammation and osteoporosis: Basic and clinical concepts. Gut 2008;57:684–4.PubMedCrossRef
12.
Lacativa PG, Farias ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol. 2010;54:123–2.PubMedCrossRef
13.
Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis. 2010;28:179–85.PubMedCrossRef
14.
Ndumele CE, Nasir K, Conceicao RD,et al. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011;31(8):1927–32.PubMedCrossRef
15.
Matthews DR, Hosker JP, Rudenski AS,et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19.PubMedCrossRef
16.
Prati D, Taioli E, Zanella A,et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1–10.PubMed
17.
Bouillon R, Auwerx J, Dekeyser L,et al. Serum vitamin D metabolites and their binding protein in patients with liver cirrhosis. J Clin Endocrinol Metab. 1984;59:86–9.PubMedCrossRef
18.
Skinner RK, Sherlock S, Long RG, Wilis MR. 25-Hydroxylation of vitamin D in primary biliary cirrhosis. Lancet 1977;1:720–1PubMedCrossRef
19.
Nakchbandi IA, Van Der Merwe SW. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:660–70PubMedCrossRef
20.
Hwang DK, Choi HJ. The relationship between low bone mass and metabolic syndrome in Korean women. Osteoporos Int. 2009;21(3):425–31.PubMedCrossRef
21.
22.
Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941–66.PubMedCrossRef
23.
Schiefke I, Fach A, Wiedmann M,et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol. 2005;11:1843–7.PubMed
24.
Guggenbuhl P, Deugnier Y, Boisdet JF,et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int. 2005;16:1809–14.PubMedCrossRef
25.
Hegedus D, Ferencz V, Lakatos PL,et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res. 2002;17:1961–7.CrossRef
26.
Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: Effects of medical treatment. Am J Gastroenterol. 1994;89:47–50.PubMed
27.
Levy C, Lindor KD. Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clin Liver Dis. 2003;7:901–0.PubMedCrossRef
28.
Bauer DC, Sklarin PM, Stone KL,et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: The study of osteoporotic fractures. J Bone Miner Res. 1999;14:1404-0.PubMedCrossRef
29.
Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003;124:795–41.PubMedCrossRef
30.
Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res. 2000;15:1398–04.PubMedCrossRef
31.
Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007;102:2716–7.PubMedCrossRef
32.
Babali A, Cakal E, Purnak T,et al. Serum alpha-fetoprotein levels in liver steatosis. Hepatol Int. 2009;3(4):551–5.PubMedCrossRef
33.
Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102:2708–15.PubMedCrossRef
Metadaten
Titel
The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease
verfasst von
Tugrul Purnak, MD
Yavuz Beyazit, MD
Asso. Prof. Ersan Ozaslan, MD
Cumali Efe, MD
Merve Hayretci, MD
Publikationsdatum
01.08.2012
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-012-0211-4

Weitere Artikel der Ausgabe 15-16/2012

Characterization of the extended-spectrum b-lactamases and determination of the virulence factors of uropathogenic Escherichia coli strains isolated from children

  • original article

Mitteilungen August 2012

  • mitteilungen der gesellschaft

Smoking and lung cancer: current trends in Austria

  • original article

43. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin

  • Abstracts

Central venous to arterial pCO2 difference in cardiogenic shock

  • original article

Measuring quality of life with the German Osteoporosis Quality of Life Questionnaire in women with osteoporosis

  • original article